WallStSmart

AbbVie Inc (ABBV)vsInteger Holdings Corp (ITGR)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 3516% more annual revenue ($66.01B vs $1.83B). ABBV leads profitability with a 15.7% profit margin vs 5.7%. ABBV appears more attractively valued with a PEG of 0.60. ABBV earns a higher WallStSmart Score of 77/100 (B+).

ABBV

Strong Buy

77

out of 100

Grade: B+

Growth: 6.7Profit: 9.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

ITGR

Hold

41

out of 100

Grade: D

Growth: 4.0Profit: 5.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 1.93
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-85.2%)

Margin of Safety

-85.2%

Fair Value

$157.29

Current Price

$294.48

$137.19 premium

UndervaluedFair: $157.29Overvalued
ITGRUndervalued (+6.6%)

Margin of Safety

+6.6%

Fair Value

$93.36

Current Price

$126.42

$33.06 discount

UndervaluedFair: $93.36Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$521.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
37.2%10/10

Strong operational efficiency at 37.2%

EPS GrowthGrowth
2282.0%10/10

Earnings expanding 2282.0% YoY

Debt/EquityHealth
-17.6510/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.608/10

Growing faster than its price suggests

ITGR1 strengths · Avg: 8.0/10
Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
50.7x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

ITGR4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.934/10

Grey zone — moderate risk

Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.812/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.

Bull Case : ITGR

The strongest argument for ITGR centers on Price/Book.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.

Bear Case : ITGR

The primary concerns for ITGR are Altman Z-Score, Profit Margin, Piotroski F-Score. A P/E of 42.5x leaves little room for execution misses.

Key Dynamics to Monitor

ABBV profiles as a mature stock while ITGR is a value play — different risk/reward profiles.

ITGR carries more volatility with a beta of 0.58 — expect wider price swings.

ABBV is growing revenue faster at 10.3% — sustainability is the question.

ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (77/100 vs 41/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Integer Holdings Corp

HEALTHCARE · MEDICAL DEVICES · USA

Integer Holdings Corporation is an outsourced manufacturer of medical devices in the United States, Puerto Rico, Costa Rica, and internationally. The company is headquartered in Plano, Texas.

Want to dig deeper into these stocks?